-
Paired monoclonal antibodies to COVID-19 nucelocapsid
Paired monoclonal antibodies to COVID-19 nucelocapsid
- 中文名称：
- Paired monoclonal antibodies to COVID-19 nucelocapsid
- 英文名称：
- Paired monoclonal antibodies to COVID-19 nucelocapsid
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA14650
- 规格：
- 1 Pair|2x1 Pair|3x1 Pair|4x1 Pair|
- 保存建议：
- Store at -20°C. Avoid repeated freeze/thaw cycles.
- 货期：
- 6-8周
- 纯度：
- Purified by Protein A affinity column
- 产品形式：
- Purified, Liquid; PBS, pH 7.4 (with 0.1 % NaN3)
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
COVID-19 (coronavirus) also known as: SARS-CoV-2, 2019 Novel Coronavirus or Wuhan Coronavirus
Reference Data: The information in this section is for reference only. Covid-Mab3 has been used as the capture/coating antibody over the membrane at 2.2 mg/ml. Covid-Mab4 has used as the conjugation antibody conjugated to colloid. However, each laboratory should develop their own protocols based on their experience and expertise.
A laboratory study using the paired Covid-Mab3 and Covid-Mab4 antibodies showed the antibodies detected a low level of recombinant Covid 19 nucleocapsid protein (Cat no. MBS596190) down to 180pg/ml. Lowest detection (LoD) of TCID50/ml for inactivated SARS-CoV-2 virus WA1/2020 (NR-52286) from was 6.6 x 103; this number is comparable to some COVID antigen rapid tests approved by the FDA. In this study, level of recombinant Covid 19 nucleocapsid protein (Cat no MBS596190) down to 180pg/ml. Lowest detection (LoD) of TCID50/ml for inactivated SARS-CoV-2 virus WA1/2020 (NR-52286) from was 6.6 x 103; this number is comparable to some COVID antigen rapid tests approved by the FDA. In this study, Two independent clinical studies were conducted using Clones Covid-Mab3 and Covid-Mab4 in rapid antigen tests. One clinical study was conducted in the Philippines, USA, and India and included 193 infected COVID-19 patients. The results of this study showed 91.6% sensitivity for infected patients and 100% specificity for 903 peoples without the infection. The rapid antibody test used in this study has been approved by CE marker and Health Canada.
The second clinical study was conducted in Nigeria and included 166 infected COVID-19 patients. The results of this study showed 89.5% sensitivity for infected patients, and 98.5% specificity for 67 uninfected individuals.
An additional study using Clones Covid-Mab3 and Covid-Mab4 in rapid antigen tests to detect the Omicron variant was conducted between January and February 2022 in Canada. The showed 100% positive for 25 Omicron patients and 100% specificity for the 50 uninfected people in Canada.
